Vij, Ravi

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,147

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 796

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 781

Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.

Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 666

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 616

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 259

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., et al. (2022) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 252

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 112

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood

Acute Myeloid Leukemia ResearchProtein Degradation and Inhibitors

Cited by 107

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 95

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

Ghobrial, I. M., Weller, E., Vij, R., Munshi, N. C., Banwait, R., Bagshaw, M., Schlossman, R., Leduc, R., Chuma, S., Kunsman, J., et al. (2011) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 95

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013

Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 82

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 54

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

Yao, L., Jayasinghe, R. G., Lee, B. H., Bhasin, S. S., Pilcher, W., Doxie, D. B., Gonzalez-Kozlova, E., Dasari, S., Fiala, M. A., Pita-Juarez, Y., et al. (2022) · Cancer Research Communications

Multiple Myeloma Research and TreatmentsSingle-cell and spatial transcriptomics

Cited by 45

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 31

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Cho, H. J., Costa, L. J., Davies, F. E., Neparidze, N., Vij, R., Feng, Y., Teterina, A., Wassner Fritsch, E., Wenger, M., & Kaufman, J. L. (2018) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 21

P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

Ramasamy, K., Goldschmidt, H., Moreau, P., Petrucci, M.-T., Kuter, D., Durie, B., Cella, D., Dhanda, D., Gu, J., Amin, S., et al. (2023) · HemaSphere

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3